Topic: rheumatoid arthritis
Gilead and Galapagos have notched another series of late-stage wins for their JAK inhibitor filgotinib.
The Big Pharma has culled a dual amylin calcitonin receptor agonist, a BTK inhibitor and a urocortin-2 peptide.
Olumiant eventually nabbed the nod it needed to take on Pfizer’s Xeljanz, the only other drug in its class approved for rheumatoid arthritis, but with caveats.
Capitalizing on a process the body uses to eliminate overly aggressive T cells could be a new way to treat autoimmune diseases.
J&J picked up the rights to the CD28 antagonist for €10 million upfront in 2016, but clinical progress stalled following the deal.
The highest dose of the anti-GM-CSF antibody failed to beat the placebo on a disease activity score, but GSK plans to run more trials nonetheless.
The most advanced drug to get the chop is RG6125, an anti-cadherin 11 antibody that entered a phase 2 rheumatoid arthritis trial last year.
Royal Philips and Ypsomed plan to install digital, at-home adherence tracking across a line of connected injection and infusion systems.
The data suggest filgotinib is safe and as effective as JAK rivals including AbbVie’s upadacitinib, setting the stage for a four-way commercial scrap.
The past week’s biotech news included insight into how ApoE4 raises Alzheimer’s risk and a peptide vaccine for broad flu protection.